In glioblastoma cell populations that frequently harbor epidermal growth factor receptor (EGFR) mutations and upregulation, Karpel-Massler et al. studied the oncogenic EGFR pathway and RAC1’s role in therapeutic resistance to EGFR TKIs such as erlotinib. Here, RAC1 is linked to glioblastoma.